Endo International plc – Ordinary Shares (NASDAQ:ENDP) is currently working with the U.S. Food and Drug Administration. The two hope to meet their common goal towards addressing the agency’s unprecedented request. It had forwarded claims that it had pulled off the market the powerful opioid pain medication Opana ER on the basis that high rates of potential abuse were being experienced.

The FDA was compelled to get in touch with Endo eventually ordering it to quit selling the drug. This happened in the course of last week and has been described by top analysts as the first time the agency made such a drastic move. This is amid what the agency has commonly been referring to as a public-health crisis.

One thing that seems quite evident from the look at the whole matter is the fact that the agency seems to be doing all within its means to contain an outbreak of dangerous infections among addicts, who have continued to turn a deaf ear to its warnings against abusing drugs such as Opana ER.

According to, such addicts have been riding on the fact that the drugs they have been abusing had been approved for legitimate pain relief. The agency through one of its top officials expressed its disgust upon the behavior condemning it in a big way.

The agency has also called upon Endo to be mindful of the needs of those patients who use the medication for the right purposes. During a presentation at the Goldman Sachs Healthcare Conference, Campanelli who is a top official working with Endo said, “The request to voluntarily remove the product is one thing, but it comes with a lot of other questions that are unanswered. We are attempting to communicate with the FDA to find out what they would like us to do.”

The company had earlier made efforts to reformulate the drug to try and cut down its potential for abuse. Things turned out a lot worse since users went ahead to crush it and inject it in their systems.